SynthesisBMC ophthalmology2026
Efficacy and safety of PreserFlo MicroShunt versus trabeculectomy in glaucoma patients: a systematic review, meta-analysis, and meta-regression of clinical outcomes and key covariates.
Synthesis in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePreserFlo MicroShunt (a subconjunctival drainage device classified as minimally invasive bleb surgery [MIBS]) has been adopted as a less invasive alternative to trabeculectomy, but comparative evidence across clinical outcomes and safety profiles remains heterogeneous. We synthesized current comparative data on efficacy and complications and explored key covariates using meta-regression.
designSystematic Review and Meta-Analysis.
methodsWe conducted a PRISMA-compliant systematic review of PubMed, Embase, and Scopus from inception through December 2025. Comparative studies of PreserFlo versus trabeculectomy reporting extractable outcomes were included. Random-effects meta-analyses were performed for continuous outcomes (mean difference, inverse-variance) and dichotomous outcomes (odds ratio, Mantel–Haenszel). Meta-regression evaluated prespecified covariates (e.g., age, baseline IOP, medication burden, pseudophakia, prior surgery, follow-up). Sensitivity analyses (leave-one-out) and publication-bias assessments (funnel plots/Egger) were performed.
resultsFourteen studies (2,229 patients; follow-up 2–24 months) were included. Compared with trabeculectomy, PreserFlo was associated with higher postoperative IOP (MD 1.44 mmHg; 95% CI 0.64–2.24) and smaller IOP reduction (MD − 2.73 mmHg; 95% CI − 3.84 to − 1.61), with moderate-to-high heterogeneity. Rates of complete and qualified success were similar between procedures (OR 0.95 and 0.97, respectively). PreserFlo was associated with lower odds of hypotony maculopathy (OR 0.31; 95% CI 0.12–0.78) and fewer overall postoperative complications (OR 0.48; 95% CI 0.38–0.60). Evidence of small-study effects was observed for selected outcomes.
conclusionPreserFlo demonstrates similar surgical success rates to trabeculectomy but provides less overall IOP reduction, while showing a more favorable complication profile, particularly regarding hypotony maculopathy and overall postoperative events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.